$0.14 EPS Expected for Daktronics, Inc. (DAKT); Neos Therapeutics (NEOS) SI Decreased By 29.26%

November 20, 2017 - By Winifred Garcia

Neos Therapeutics Incorporated (NASDAQ:NEOS) had a decrease of 29.26% in short interest. NEOS’s SI was 2.56M shares in November as released by FINRA. Its down 29.26% from 3.62 million shares previously. With 1.51M avg volume, 2 days are for Neos Therapeutics Incorporated (NASDAQ:NEOS)’s short sellers to cover NEOS’s short positions. The SI to Neos Therapeutics Incorporated’s float is 21.52%. The stock decreased 3.33% or $0.35 on November 17, reaching $10.15. About shares traded. Neos Therapeutics Inc (NASDAQ:NEOS) has risen 9.07% since November 20, 2016 and is uptrending. It has underperformed by 7.63% the S&P500.

Analysts expect Daktronics, Inc. (NASDAQ:DAKT) to report $0.14 EPS on November, 21 before the open.They anticipate $0.06 EPS change or 30.00% from last quarter’s $0.2 EPS. DAKT’s profit would be $6.20M giving it 17.75 P/E if the $0.14 EPS is correct. After having $0.19 EPS previously, Daktronics, Inc.’s analysts see -26.32% EPS growth. The stock decreased 0.50% or $0.05 on November 17, reaching $9.94. About shares traded. Daktronics, Inc. (NASDAQ:DAKT) has risen 24.81% since November 20, 2016 and is uptrending. It has outperformed by 8.11% the S&P500.

Among 7 analysts covering Neos Therapeutics (NASDAQ:NEOS), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Neos Therapeutics had 21 analyst reports since August 17, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Outperform” on Thursday, November 12. The rating was initiated by BMO Capital Markets with “Outperform” on Wednesday, June 29. JMP Securities maintained Neos Therapeutics Inc (NASDAQ:NEOS) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $32 target. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, August 9. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Buy” rating given on Tuesday, June 20 by BMO Capital Markets. The stock has “Buy” rating by RBC Capital Markets on Tuesday, August 8. The rating was initiated by JMP Securities on Monday, August 17 with “Market Outperform”. The firm has “Buy” rating by BMO Capital Markets given on Friday, September 15. The stock of Neos Therapeutics Inc (NASDAQ:NEOS) has “Buy” rating given on Thursday, September 14 by RBC Capital Markets. The firm has “Outperform” rating by Wells Fargo given on Friday, February 19.

Neos Therapeutics, Inc. is a pharmaceutical company. The company has market cap of $294.32 million. The Firm is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. It currently has negative earnings. The Company’s segment is engaged in the development, manufacturing and commercialization of pharmaceuticals.

Since June 9, 2017, it had 0 buys, and 3 sales for $247,233 activity. MULLIGAN JOHN L sold $157,354 worth of Daktronics, Inc. (NASDAQ:DAKT) on Tuesday, June 13. $55,182 worth of Daktronics, Inc. (NASDAQ:DAKT) was sold by ANDERSON BYRON J on Friday, June 9. $34,697 worth of stock was sold by FRAME NANCY D on Friday, June 9.

Daktronics, Inc. is a supplier of electronic scoreboards, electronic display systems, digital messaging solutions, software and services for sporting, commercial and transportation applications. The company has market cap of $440.22 million. The Firm operates through five divisions: Commercial, Live Events, High School Park and Recreation, Transportation, and International. It has a 33.32 P/E ratio. The Firm offers a range of products, from small scoreboards and electronic displays to video display systems, as well as related control, timing and sound systems.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com